down arrow

Universe Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG9442G1120
USD
4.18
0.06 (1.46%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.924.20

52 Week

2.51197.20
Valuation
Technical
Day's Volume

CASH

8.63 k

Shareholding (Sep 2024)

FII

0.17%

Held by 2 FIIs

DII

99.83%

Held by 0 DIIs

Promoter

0.00%

How big is Universe Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Universe Pharmaceuticals, Inc. has a market capitalization of 2.24 million and reported net sales of 162.49 million with a net profit loss of 315.54 million for the latest four quarters. The balance sheet as of Sep 24 shows shareholder's funds of 45.50 million and total assets of 67.95 million.

As of Jun 18, Universe Pharmaceuticals, Inc. has a market capitalization of 2.24 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 12, the company reported net sales of 162.49 million for the latest four quarters. However, it also experienced a net profit loss of 315.54 million during the same period.<BR><BR>As of Sep 24, the balance sheet shows shareholder's funds amounting to 45.50 million and total assets of 67.95 million.

Read More

What does Universe Pharmaceuticals, Inc. do?

22-Jun-2025

Universe Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $19 million and a net loss of $77 million as of June 2012. The company has a market cap of $2.24 million and no dividend yield.

Overview: <BR>Universe Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 19 Million (Quarterly Results - Jun 2012) <BR>Most recent Net Profit: -77 Million (Quarterly Results - Jun 2012) <BR>Market-cap: USD 2.24 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.47 <BR>Return on Equity: -999,999.00% <BR>Price to Book: 0.05<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Universe Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Universe Pharmaceuticals, Inc. shows a neutral trend with mixed signals, mildly bullish indicators on weekly and monthly MACD, while outperforming the S&P 500 recently, but has significantly negative year-to-date and one-year returns.

As of 11 September 2025, the technical trend for Universe Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands indicate a bullish trend weekly but are mildly bearish monthly. Daily moving averages are mildly bearish, and the KST shows a mildly bullish weekly trend but bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, while the OBV is bullish monthly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 1.72% and 21.4%, respectively, compared to 1.05% and 2.33% for the index. However, the year-to-date and one-year returns are significantly negative at -82.99% and -98.06%, respectively, contrasting sharply with the S&P 500's positive returns.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.72

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

0.04

Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2012)
Net Profit:
-77 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.75%
0%
17.75%
6 Months
-0.48%
0%
-0.48%
1 Year
-90.05%
0%
-90.05%
2 Years
-99.31%
0%
-99.31%
3 Years
154.88%
0%
154.88%
4 Years
-99.93%
0%
-99.93%
5 Years
0%
0%
0.0%

Universe Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Universe Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Universe Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands indicate a bullish trend weekly but are mildly bearish monthly. Daily moving averages are mildly bearish, and the KST shows a mildly bullish weekly trend but bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, while the OBV is bullish monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 1.72% and 21.4%, respectively, compared to 1.05% and 2.33% for the index. However, the year-to-date and one-year returns are significantly negative ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-13.58%
EBIT Growth (5y)
-6.56%
EBIT to Interest (avg)
-0.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
3.18
Tax Ratio
3.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.87%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.05
EV to EBIT
-0.49
EV to EBITDA
-0.36
EV to Capital Employed
-0.80
EV to Sales
-0.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1055.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'12 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2012 is -78.17% vs 15.13% in Jun 2011",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2012 is -155.63% vs -308.11% in Jun 2011",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'12",
        "Jun'11",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.10",
          "val2": "87.50",
          "chgp": "-78.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.40",
          "val2": "-66.70",
          "chgp": "84.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.90",
          "val2": "18.80",
          "chgp": "-42.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "27.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.20",
          "val2": "-30.20",
          "chgp": "-155.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2023 is -19.45% vs -16.46% in Sep 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2023 is 28.74% vs -176.99% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.30",
          "val2": "40.10",
          "chgp": "-19.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-6.90",
          "chgp": "56.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-8.70",
          "chgp": "28.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-109.20%",
          "val2": "-185.30%",
          "chgp": "7.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'12 - YoYstock-summary
Jun'12
Jun'11
Change(%)
Net Sales
19.10
87.50
-78.17%
Operating Profit (PBDIT) excl Other Income
-10.40
-66.70
84.41%
Interest
10.90
18.80
-42.02%
Exceptional Items
27.50
0.00
Consolidate Net Profit
-77.20
-30.20
-155.63%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2012 is -78.17% vs 15.13% in Jun 2011

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2012 is -155.63% vs -308.11% in Jun 2011

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'23stock-summary
Sep'23
Sep'22
Change(%)
Net Sales
32.30
40.10
-19.45%
Operating Profit (PBDIT) excl Other Income
-3.00
-6.90
56.52%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.20
-8.70
28.74%
Operating Profit Margin (Excl OI)
-109.20%
-185.30%
7.61%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2023 is -19.45% vs -16.46% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2023 is 28.74% vs -176.99% in Sep 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Universe Pharmaceuticals, Inc. stock-summary
stock-summary
Universe Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."